Skip to content

Exelixis EXEL Preferred Stock

Preferred Stock at other companies

Summit Therapeutics logo
Summit TherapeuticsSMMT
$0
Incyte logo
IncyteINCY
$0
BridgeBio Pharma logo
BridgeBio PharmaBBIO
$0
Neurocrine Biosciences logo
Neurocrine BiosciencesNBIX
$0
United Therapeutics logo
United TherapeuticsUTHR
$0
ALN
Alnylam PharmaceuticalsALNY

Other financials

Income statement

See full
Revenue$610.8M+10.0%
Gross profit$590.9M+10.2%
Operating income$251.3M+34.5%
Net income$210.5M+31.9%
EPS (diluted)$0.79+43.6%

Balance sheet

See full
Cash & equivalents$226.2M+23.1%
Total debt$169.5M-9.4%
Total equity$1.9B-9.2%
Total assets$2.6B-8.6%

Cash flow

See full
Operating cash flow$251.8M+19.1%
CapEx$1.5M-48.9%
Free cash flow$250.3M+20.1%

Valuation

See full
Market cap$13.05B+10.1%
Enterprise value$12.99B+9.5%
P/E15.7×-2.8×
P/S5.5×+0.3×

Profitability

See full
Gross margin96.4%-0.3pp
Operating margin39.4%+6.3pp
Net margin35.1%+7.1pp
FCF margin38.6%+2.9pp

Returns & leverage

See full
Return on equity41%+10.8pp
Debt / equity0.1×0.0×
Current ratio3.3×-0.2×

Where this comes from

Reported directly by Exelixis in its filing.

Tagged under the XBRL concept us-gaap:PreferredStockValue.

The official record: Exelixis’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Exelixis's preferred stock.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Exelixis's preferred stock?
Exelixis (EXEL) reported preferred stock of $0 in Q1 2026.
What does preferred stock mean?
The value of shares that have priority over common stock regarding dividends and asset liquidation.
How do you interpret preferred stock?
An increase indicates the issuance of senior equity to raise capital, while a decrease reflects redemption or conversion into common stock.
How does preferred stock compare across companies?
Most biotech firms rely primarily on common equity; preferred stock is often used for specific financing rounds or strategic partnerships.